# Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)

> **NCT06080256** · PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 80 (estimated)

## Conditions studied

- Intracranial Atherosclerosis
- Atherosclerotic Plaque
- Stenosis

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT06080256
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-30
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06080256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06080256, "Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06080256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*